Clinical Trial Update: A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABT-888 plus carboplatin versus carboplatin with standard chemotherapy versus standard chemotherapy in early-stage triple-negative brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ABT-888 (veliparib)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: AbbVie | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: COMPLETED